IL1B and colorectal carcinoma: Experimental evidence indicates that simvastatin exerts a pronounced suppressive effect on neoplastic cell–elicited pro-inflammatory immunocytokine release—specifically attenuating IL-1 family β-isoform and type II interferon output—while concomitantly restraining the proliferative kinetics of colorectal carcinoma cells [217,218].